AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

Background & Aims: Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical assessment of the existing data...

Full description

Bibliographic Details
Main Authors: Altayar, O. (Author), Estfan, B. (Author), Falck-Ytter, Y. (Author), O'Shea, R. (Author), Shah, R. (Author), Su, G.L (Author), Sultan, S. (Author), Wenzell, C. (Author)
Format: Article
Language:English
Published: W.B. Saunders 2022
Subjects:
adjuvant chemotherapy
anilide
Anilides
Antibodies, Monoclonal, Humanized
antineoplastic agent
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
atezolizumab
bevacizumab
Bevacizumab
cabozantinib
carbanilamide derivative
Carcinoma, Hepatocellular
chemoembolization
Chemoembolization, Therapeutic
Chemotherapy, Adjuvant
Hepatectomy
Hepatocellular Carcinoma
human
Humans
lenvatinib
Liver Cancer
liver cell carcinoma
Liver Neoplasms
liver resection
liver transplantation
Liver Transplantation
liver tumor
monoclonal antibody
pathology
pathophysiology
pembrolizumab
Phenylurea Compounds
practice guideline
pyridine derivative
Pyridines
quinoline derivative
Quinolines
ramucirumab
regorafenib
retreatment
Retreatment
sorafenib
Sorafenib
Systemic Therapy
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items